Citation Export
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Gi Ru | - |
dc.contributor.author | Kim, Hee Eun | - |
dc.contributor.author | Ju, Hyeon Jin | - |
dc.contributor.author | Kim, Jae Ho | - |
dc.contributor.author | Choi, Sangdun | - |
dc.contributor.author | Choi, Hak Soo | - |
dc.contributor.author | Kim, Moon Suk | - |
dc.date.issued | 2022-12-01 | - |
dc.identifier.issn | 2590-0064 | - |
dc.identifier.uri | https://dspace.ajou.ac.kr/dev/handle/2018.oak/32849 | - |
dc.description.abstract | Triple-negative breast cancer (TNBC) patients are considered intractable, as this disease has few effective treatments and a very poor prognosis even in its early stages. Here, intratumoral therapy with resveratrol (Res), which has anticancer and metastasis inhibitory effects, was proposed for the effective treatment of TNBC. An injectable Res-loaded click-crosslinked hyaluronic acid (Res-Cx-HA) hydrogel was designed and intratumorally injected to generate a Res-Cx-HA depot inside the tumor. The Res-Cx-HA formulation exhibited good injectability into the tumor tissue, quick depot formation inside the tumor, and the depot remained inside the injected tumor for extended periods. In vivo formed Res-Cx-HA depots sustained Res inside the tumor for extended periods. More importantly, the bioavailability and therapeutic efficacy of Res remained almost exclusively within the tumor and not in other organs. Intratumoral injection of Res-Cx-HA in animal models resulted in significant negative tumor growth rates (i.e., the tumor volume decreased over time) coupled with large apoptotic cells and limited angiogenesis in tumors. Therefore, Res-Cx-HA intratumoral injection is a promising way to treat TNBC patients with high efficacy and minimal adverse effects. | - |
dc.description.sponsorship | This study was supported by the National Research Foundation of Korea (NRF) grants, Creative Materials Discovery Program ( 2019M3D1A1078938 ) and Priority Research Centers Program ( 2019R1A6A1A11051471 ). | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier B.V. | - |
dc.subject.mesh | Cancer patients | - |
dc.subject.mesh | Click-crosslinking | - |
dc.subject.mesh | Cross-linked hydrogels | - |
dc.subject.mesh | Crosslinked | - |
dc.subject.mesh | Inhibitory effect | - |
dc.subject.mesh | Injectable hydrogels | - |
dc.subject.mesh | Injectables | - |
dc.subject.mesh | Intratumoral injection | - |
dc.subject.mesh | Therapeutic effects | - |
dc.subject.mesh | Triple-negative breast cancers | - |
dc.title | Injectable click-crosslinked hydrogel containing resveratrol to improve the therapeutic effect in triple negative breast cancer | - |
dc.type | Article | - |
dc.citation.title | Materials Today Bio | - |
dc.citation.volume | 16 | - |
dc.identifier.bibliographicCitation | Materials Today Bio, Vol.16 | - |
dc.identifier.doi | 10.1016/j.mtbio.2022.100386 | - |
dc.identifier.scopusid | 2-s2.0-85135954455 | - |
dc.identifier.url | www.journals.elsevier.com/materials-today-bio | - |
dc.subject.keyword | Click-crosslinking | - |
dc.subject.keyword | Injectable hydrogel | - |
dc.subject.keyword | Intratumoral injection | - |
dc.subject.keyword | Resveratrol | - |
dc.subject.keyword | Triple-negative breast cancer | - |
dc.description.isoa | true | - |
dc.subject.subarea | Biotechnology | - |
dc.subject.subarea | Bioengineering | - |
dc.subject.subarea | Biomaterials | - |
dc.subject.subarea | Biomedical Engineering | - |
dc.subject.subarea | Molecular Biology | - |
dc.subject.subarea | Cell Biology | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.